EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Engineering a novel asymmetric head-to-tail (HtT) 1+1 and 2+1 T cell bispecific antibody (TCB) platform with superior T cell killing compared to 1+1 bispecific IgG antibodies

Omar Abdelmotaleb, Antonio Sorrentino, Christiane Neumann, Tanja Fauti, Tina Weinzierl, Anne Freimoser-Grundschober, Claudia Ferrara Koller, Linda Arnold, Sylvia Herter, Matthias E Lauer, Philippe Ringler, Clara Albani, Simone Lang, Sarah Diggelmann, Florian Limani, Sara Colombetti, Johannes Sam, Erwin Puijenbroek, Ekkehard Moessner, Peter Brünker, Marina Bacac, Pablo Umana, Christian Klein, Inja Waldhauer

Antibody Therapeutics · 2026-11-08

DOI: 10.1093/abt/tbag057 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background: The overall activity of T cell engaging bispecific antibodies (TCBs) is governed by an interplay of various factors including antigen density, binding epitope, affinity, and molecular geometry. Conventional 1+1 IgG-like-TCBs represent the most utilized format amongst approved TCBs and offer prolonged pharmacokinetics via silenced Fc domains. Nevertheless, head-to-tail (HtT) formats, such as the 2+1 TCBs, have gained interest more recently. Methods: Here, we systematically evaluated HtT configurations, including 1+1 one-armed (OA), 2+1 classical, and 2+1 inverted TCB formats, against standard 1+1 IgG-like TCBs across CEACAM5, FOLR1, MCSP, and CD20 as tumor antigens. Assessments included in vitro functional assays, in vivo humanized mouse models, and biophysical characterization via negative-stain transmission electron microscopy (NS-TEM) and liquid-state atomic force microscopy (AFM). Results: HtT geometries consistently outperformed standard 1+1 IgG-like TCBs in tumor cell lysis, T-cell activation, and tumor growth inhibition. Biophysical analyses confirmed that the 2+1 inverted format possesses exceptional conformational flexibility, behaving as freely jointed rigid segments. Crucially, by positioning the CD3-binding site internally, the 2+1 inverted format circumvents N-terminal steric restrictions of the tumor antigen binder, preserving high-avidity tumor engagement. Furthermore, in vivo evaluation demonstrated that the HtT configuration remains highly efficacious in combination with standard bivalent CD20 monoclonal antibodies. Conclusions: The asymmetric inverted configurations of TCBs represent a robust, versatile, and highly combinable platform for next-generation TCB design.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →